About CHINARES PHARMA Company

China Resources Pharmaceutical Group Co., Ltd. (stock code: 3320) is a leading comprehensive pharmaceutical company in China. Its business scope covers the production, distribution and retail of pharmaceuticals and health products. The Group was founded in 2007 and has now developed into one of the top five pharmaceutical manufacturers in China and the top three distributors of pharmaceutical products in China (by revenue). The Company successfully completed its global sale in Hong Kong in October 2016. Our manufacturing business covers R&D, production and sales of pharmaceuticals and health care products. We produce 792 kinds of drugs, of which 430 products have entered the national medical insurance catalogue. The product portfolio includes chemicals, traditional Chinese medicine, biopharmaceuticals and nutritional health products, covering a wide range of therapeutic areas, including cardiovascular, digestive tract and metabolism, high-volume intravenous injections, pediatrics, respiratory system, skin, etc. Furthermore, we have many well-known brands such as “999,” “Donga Ejiao,” “Shuanghe,” “Zizhu,” “Jiangzhong,” “Boya,” and “Kunming Traditional Chinese Medicine,” and our business covers categories such as colds, gastrointestinal, skin, pediatrics, orthopedics, and blood products. In the future, we will actively expand to health management and chronic disease management products to meet the full cycle and multi-level health needs of Chinese families from prevention, care, treatment, and rehabilitation. We regard R&D innovation as an important driving force for long-term development, and continue to increase investment in R&D. We have a national key laboratory, five national engineering technology research centers, a national industrial innovation center, three national enterprise technology centers, more than 70 provincial and municipal R&D platforms, and postdoctoral research workstations. With our comprehensive product supply and extensive distribution network, we distribute products directly to hospitals and other medical institutions in China. We operate a nationwide distribution network composed of more than 220 logistics centers, strategically covering 28 provinces, municipalities and autonomous regions in China. The number of customers exceeds 0.21 million, including more than 10,000 secondary and tertiary hospitals, and about 90,000 customers in primary care institutions. Additionally, we operate one of the largest retail pharmacy networks in China. We operate 760 retail pharmacies under high-quality national or regional brands such as “China Resources Tang” and “Dexin Bank”, including 275 pharmacies specializing in DTP (including 162 “dual channel” pharmacies).